← Back to Clinical Trials
Recruiting NCT06471621

NCT06471621 Precision Medicine in Cardiovascular Surgery Associated Acute Kidney Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06471621
Status Recruiting
Phase
Sponsor Insel Gruppe AG, University Hospital Bern
Condition Acute Kidney Injury
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-06-16
Primary Completion 2026-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-06-16 with a primary completion date of 2026-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this prospective observational study is to define a risk profile for cardiovascular surgery associated acute kidney injury (AKI), using clinical patient characteristics, operation parameters as well as blood and urine laboratory values. The main question it aims to answer is: • Does a combination of the factors mentioned above better predict patient outcome than classical factors used to date in clinical practice? Participants of this study are adults aged 18 and above who are scheduled for elective heart or main artery surgery, and who have given written informed consent.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing elective cardiovascular surgery, such as valvular replacement surgery, with or without combined coronary artery bypass graft (CABG), or thoracic or abdominal aortic surgery. * Written informed consent obtained prior to surgery. Exclusion Criteria: * Patients with a kidney transplant or on renal replacement therapy * Severe liver failure, defined by the presence of encephalopathy, Factor V \< 50% and INR \>1.5 on preoperative blood sample (within 4 weeks).

Contact & Investigator

Central Contact

Uyen Huynh-Do, Prof. MD

✉ uyen.huynh-do@insel.ch

📞 +41316323144

Principal Investigator

Uyen Huynh-Do, Prof. MD

PRINCIPAL INVESTIGATOR

University Hospital Bern (Inselspital)

Frequently Asked Questions

Who can join the NCT06471621 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06471621 currently recruiting?

Yes, NCT06471621 is actively recruiting participants. Contact the research team at uyen.huynh-do@insel.ch for enrollment information.

Where is the NCT06471621 trial being conducted?

This trial is being conducted at Bern, Switzerland.

Who is sponsoring the NCT06471621 clinical trial?

NCT06471621 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Uyen Huynh-Do, Prof. MD at University Hospital Bern (Inselspital). The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology